Skip to main content Accessibility help

Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target

  • Neetu Singh (a1), Aseem Pandey (a1) and Suresh K. Mittal (a1)


The unprecedented global spread of highly pathogenic avian H5N1 influenza viruses within the past ten years and their extreme lethality to poultry and humans has underscored their potential to cause an influenza pandemic. Combating the threat of an impending H5N1 influenza pandemic will require a combination of pharmaceutical and nonpharmaceutical intervention strategies. The emergence of the H1N1 pandemic in 2009 emphasised the unpredictable nature of a pandemic influenza. Undoubtedly, vaccines offer the most viable means to combat a pandemic threat. Current egg-based influenza vaccine manufacturing strategies are unlikely to be able to cater to the huge, rapid global demand because of the anticipated scarcity of embryonated eggs in an avian influenza pandemic and other factors associated with the vaccine production process. Therefore, alternative, egg-independent vaccine manufacturing strategies should be evaluated to supplement the traditional egg-derived influenza vaccine manufacturing. Furthermore, evaluation of dose-sparing strategies that offer protection with a reduced antigen dose will be critical for pandemic influenza preparedness. Development of new antiviral therapeutics and other, nonpharmaceutical intervention strategies will further supplement pandemic preparedness. This review highlights the current status of egg-dependent and egg-independent strategies against an avian influenza pandemic.


Corresponding author

*Corresponding author: Suresh K. Mittal, Department of Comparative Pathobiology, School of Veterinary Medicine, Purdue University, 725 Harrison Street, West Lafayette, IN 47907, USA. E-mail:


Hide All
1Johnson, N.P. and Mueller, J. (2002) Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bulletin of the History of Medicine 76, 105-115
2de Jong, J.C. et al. (2000) Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. Journal of Medical Virology 61, 94-99
3Kawaoka, Y., Krauss, S. and Webster, R.G. (1989) Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. Journal of Virology 63, 4603-4608
4Scholtissek, C. et al. (1978) On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology 87, 13-20
5Webster, R.G. et al. (1992) Evolution and ecology of influenza A viruses. Microbiological Reviews 56, 152-179
6Taubenberger, J.K. et al. (2005) Characterization of the 1918 influenza virus polymerase genes. Nature 437, 889-893
7Smith, G.J. et al. (2009) Dating the emergence of pandemic influenza viruses. Proceedings of the National Academy of Sciences of the United States of America 106, 11709-11712
8Dawood, F.S. et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. New England Journal of Medicine 360, 2605-2615
9Bender, C. et al. (1999) Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology 254, 115-123
10Centers for Disease Control (1997) Isolation of avain influenza A (H5N1) viruses from humans – Hong Kong May–December 1997. Morbidity and Mortality Weekly Report 46, 1204-1207
11Katz, J.M. et al. (1999) Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. Journal of Infectious Diseases 180, 1763-1770
12Matrosovich, M. et al. (1999) The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. Journal of Virology 73, 1146-1155
13Shortridge, K.F. et al. (1998) Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 252, 331-342
14Yuen, K.Y. et al. (1998) Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351, 467-471
15Subbarao, K. et al. (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279, 393-396
16Centers for Disease Control (2003) Update: Influenza activity – United States and Worldwide, 2002–2003 season and composition of the 2003–2004 influenza vaccine. Morbidity and Mortality Weekly Report 52, 516-521
17WHO (2009) Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO.
18Liu, D. et al. (2009) Interspecies transmission and host restriction of avian H5N1 influenza virus. Science in China Series C Life Sciences 52, 428-438
19Guo, Y.J. et al. (2000) Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. Virology 267, 279-288
20Peiris, M. et al. (1999) Human infection with influenza H9N2. Lancet 354, 916-917
21Lin, Y.P. et al. (2000) Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proceedings of the National Academy of Sciences of the United States of America 97, 9654-9658
22Fouchier, R.A. et al. (2004) Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proceedings of the National Academy of Sciences of the United States of America 101, 1356-1361
23Webby, R.J. and Webster, R.G. (2003) Are we ready for pandemic influenza? Science 302, 1519-1522 (2009) CDC: 38 million doses of H1N1 vaccine available.
25Fox, M. (2010) U.S. slashes swine flu vaccine estimate.
26Donnelly, J.J. et al. (1995) Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nature Medicine 1, 583-587
27Cox, N.J. and Subbarao, K. (2000) Global epidemiology of influenza: past and present. Annual Review of Medicine 51, 407-421
28Chen, H. et al. (2006) Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proceedings of the National Academy of Sciences of the United States of America 103, 2845-2850
29U.S. FDA (2009) Influenza (Flu) antiviral drugs and related information.
30Cheung, C.L. et al. (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. Journal of Infectious Diseases 193, 1626-1629
31de, J. et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. New England Journal of Medicine 353, 2667-2672
32Moscona, A. (2005) Oseltamivir resistance–disabling our influenza defenses. New England Journal of Medicine 353, 2633-2636
33Dharan, N.J. et al. (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. Journal of the American Medical Association 301, 1034-1041
34Gooskens, J. et al. (2009) Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. Journal of the American Medical Association 301, 1042-1046
35Weinstock, D.M. and Zuccotti, G. (2009) The evolution of influenza resistance and treatment. Journal of the American Medical Association 301, 1066-1069
36Le, M.T. et al. (2008) Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE 3, e3339
37Kimm-Breschkin, J.L. et al. (2007) Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerging Infectious Diseases 13, 1354-1357
38WHO (2009) Oseltamivir resistance in immunocompromised hospital patients.
39Patel, A. and Gorman, S.E. (2009) Stockpiling antiviral drugs for the next influenza pandemic. Clinical Pharmacology and Therapeutics 86, 241-243
40De, C.E. (2006) Antiviral agents active against influenza A viruses. Nature Reviews Drug Discovery 5, 1015-1025
41Hayden, F. (2009) Developing new antiviral agents for influenza treatment: what does the future hold? Clinical Infectious Diseases 48 (Suppl 1), S3-13
42Lau, Y.F., Tang, L.H. and Ooi, E.E. (2009) A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27, 1354-1364
43Wong, J.P. et al. (2009) Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses. Current Pharmaceutical Design 15, 1269-1274
44Bell, D.M. (2006) Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerging Infectious Diseases 12, 88-94
45Hoelscher, M. et al. (2008) Vaccines against epidemic and pandemic influenza. Expert Opinion on Drug Delivery 5, 1139-1157
46Ilyinskii, P.O., Thoidis, G. and Shneider, A.M. (2008) Development of a vaccine against pandemic influenza viruses: current status and perspectives. International Reviews of Immunology 27, 392-426
47Gerdil, C. (2003) The annual production cycle for influenza vaccine. Vaccine 21, 1776-1779
48Tree, J.A. et al. (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19, 3444-3450
49Roos, R. (2009) Pandemic vaccine?making capacity rising, but still short.
50U.S. FDA (2003) Approval letter - influenza virus vaccine live, intranasal.
51Tosh, P.K., Boyce, T.G. and Poland, G.A. (2008) Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clinic Proceedings 83, 77-84
52Gorse, G.J., Belshe, R.B. and Munn, N.J. (1988) Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. Journal of Clinical Microbiology 26, 911-918
53Gorse, G.J., Belshe, R.B. and Munn, N.J. (1991) Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 100, 977-984
54Treanor, J.J. et al. (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18, 899-906
55Belshe, R.B. et al. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. New England Journal of Medicine 356, 685-696
56Ashkenazi, S. et al. (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatric Infectious Disease Journal 25, 870-879
57Fleming, D.M. et al. (2006) Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatric Infectious Disease Journal 25, 860-869
58Belshe, R.B. et al. (2000) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. Journal of Pediatrics 136, 168-175
59PATH (Program for Appropriate Technology in Health) and Oliver Wyman (2009) Influenza vaccine strategies for broad global access.
60Gabriel, G. et al. (2008) The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine 26, 956-965
61Govorkova, E.A. et al. (2005) Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. Journal of Virology 79, 2191-2198
62Nicolson, C. et al. (2005) Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23, 2943-2952
63Horimoto, T. and Kawaoka, Y. (1994) Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. Journal of Virology 68, 3120-3128
64Senne, D.A. et al. (1996) Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Diseases 40, 425-437
65Steel, J. et al. (2009) Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. Journal of Virology 83, 1742-1753
66Suguitan, A.L. Jr et al. (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Medicine 3, e360
67Joseph, T. et al. (2008) A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 378, 123-132
68WHO (2009) Tables on the clinical trials of pandemic influenza prototype vaccines.
69Desheva, J.A. et al. (2006) Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24, 6859-6866
70The European Agency for the Evaluation of Medicinal Products (2004) European Committee for Proprietary Medicinal Products. Guideline on submission of marketing authorisation applications for pandemic influenza vaccines through the centralised procedure.
71U.S. FDA (2007) Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines.
72Eichelberger, M. et al. (2008) FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26, 4299-4303
73Lin, J. et al. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368, 991-997
74Brady, M.I. and Furminger, I.G. (1976) A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity. Journal of Hygiene 77, 173-180
75Davenport, F.M. et al. (1964) Comparisons of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinins. Journal of Laboratory and Clinical Medicine 63, 5-13
76Laver, W.G. and Webster, R.G. (1976) Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine. Virology 69, 511-522
77Stephenson, I. et al. (2003) Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362, 1959-1966
78Wu, J. et al. (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clinical Infectious Diseases 48, 1087-1095
79Fazekas, G. et al. (2009) Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clinical and Vaccine Immunology 16, 437-443
80Vajo, Z. et al. (2008) Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatric Infectious Disease Journal 27, 1052-1056
81Mutsch, M. et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New England Journal of Medicine 350, 896-903
82Treanor, J.J. et al. (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New England Journal of Medicine 354, 1343-1351
83U.S. FDA (2007) approves first U.S. vaccine for humans against the avian influenza virus H5N1.
84Zangwill, K.M. et al. (2008) Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. Journal of Infectious Diseases 197, 580-583
85Leroux-Roels, I. et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370, 580-589
86Levie, K. et al. (2008) An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. Journal of Infectious Diseases 198, 642-649
87Nicholson, K.G. et al. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357, 1937-1943
88Bernstein, D.I. et al. (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. Journal of Infectious Diseases 197, 667-675
89Leroux-Roels, I. et al. (2008) Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3, e1665
90Bresson, J.L. et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367, 1657-1664
91Keitel, W.A. et al. (2008) Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. Journal of Infectious Diseases 198, 1309-1316
92Nolan, T.M. et al. (2008) Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26, 4160-4167
93Stephenson, I. et al. (2003) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21, 1687-1693
94Stephenson, I. et al. (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. Journal of Infectious Diseases 191, 1210-1215
95Baras, B. et al. (2008) Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3, e1401
96Rumke, H.C. et al. (2008) Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26, 2378-2388
97Banzhoff, A. et al. (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4, e4384
98Chotpitayasunondh, T. et al. (2008) Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS ONE 3, e4028
99Nolan, T. et al. (2008) Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26, 6383-6391
100Jennings, L.C. et al. (2008) Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infectious Diseases 8, 650-658
101Stephenson, I. et al. (2008) Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. New England Journal of Medicine 359, 1631-1633
102Galli, G. et al. (2009) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proceedings of the National Academy of Sciences of the United States of America 106, 7962-7967
103U.S. Department of Health & Human Sciences (2009) HHS awards $487 million contract to build first U.S. manufacturing facility for cell-based influenza vaccine.
104Roos, R. (2006) US awards $1 billion for cell-based flu vaccines.
105Novartis (2007) Novartis gains European approval for its innovative flu vaccine Optaflu®.
106Initiative for Vaccine Research, WHO (2007) Use of cell lines for the production of influenza virus vaccines: an appraisal of technical, manufacturing, and regulatory considerations.
107Hardy, C.T. et al. (1995) Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. Virology 211, 302-306
108Robertson, J.S. et al. (1985) Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 143, 166-174
109Schild, G.C. et al. (1983) Evidence for host-cell selection of influenza virus antigenic variants. Nature 303, 706-709
110Gregersen, J.P. (2008) A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 26, 3332-3340
111Howard, M.K., Kistner, O. and Barrett, P.N. (2008) Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biological Chemistry 389, 569-577
112Kistner, O. et al. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25, 6028-6036
113Palker, T. et al. (2004) Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants. Virus Research 105, 183-194
114Ehrlich, H.J. et al. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. New England Journal of Medicine 358, 2573-2584
115U.S. National Institutes of Health (2007) Phase 3 immunogenicity and safety study of an inactivated H5N1 influenza vaccine (whole virion, vero cell derived).
116U.S. National Institutes of Health (2008) Phase III study of a H5N1 vaccine in adults, elderly and specified risk groups.
117Ikonomou, L., Schneider, Y.J. and Agathos, S.N. (2003) Insect cell culture for industrial production of recombinant proteins. Applied Microbiology and Biotechnology 62, 1-20
118Altmann, F. et al. (1999) Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconjugate Journal 16, 109-123
119Safdar, A. and Cox, M.M. (2007) Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opinion on Investigational Drugs 16, 927-934
120Huber, V.C. and McCullers, J.A. (2008) FluBlok, a recombinant influenza vaccine. Current Opinion in Molecular Therapeutics 10, 75-85
121Roos, R. (2007) Insect-cell-based flu vaccine looks good in clinical trial.
122Lakey, D.L. et al. (1996) Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. Journal of Infectious Diseases 174, 838-841
123Powers, D.C. et al. (1997) Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. Journal of Infectious Diseases 175, 342-351
124Treanor, J.J. et al. (1996) Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. Journal of Infectious Diseases 173, 1467-1470
125Treanor, J.J. et al. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19, 1732-1737
126Goji, N.A. et al. (2008) Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. Journal of Infectious Diseases 198, 635-641
127Grgacic, E.V. and Anderson, D.A. (2006) Virus-like particles: passport to immune recognition. Methods 40, 60-65
128Ludwig, C. and Wagner, R. (2007) Virus-like particles-universal molecular toolboxes. Current Opinion in Biotechnology 18, 537-545
129Roy, P. and Noad, R. (2008) Virus-like particles as a vaccine delivery system: myths and facts. Human Vaccines 4, 5-12
130U.S. FDA (2006) FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus.
132Bright, R.A. et al. (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3, e1501
133Kang, S.M. et al. (2009) Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 4, e4667
134Mahmood, K. et al. (2008) H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26, 5393-5399
135Perrone, L.A. et al. (2009) Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. Journal of Virology 83, 5726-5734
136Hayden, F.G. et al. (2009) Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. Vaccine 27, 4079-4089
137Quan, F.S. et al. (2008) A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26, 3352-3361
138Feltquate, D.M. et al. (1997) Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. Journal of Immunology 158, 2278-2284
139Huber, V.C. et al. (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clinical and Vaccine Immunology 13, 981-990
140Ulmer, J.B. et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749
141Webster, R.G. and Robinson, H.L. (1997) DNA vaccines: a review of developments. BioDrugs 8, 273-292
142Luxembourg, A., Evans, C.F. and Hannaman, D. (2007) Electroporation-based DNA immunisation: translation to the clinic. Expert Opinion on Biological Therapy 7, 1647-1664
143Sharpe, M. et al. (2007) Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 25, 6392-6398
144Wang, S. et al. (2008) The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26, 2100-2110
145Ulmer, J.B., Wahren, B. and Liu, M.A. (2006) Gene-based vaccines: recent technical and clinical advances. Trends in Molecular Medicine 12, 216-222
146Huber, V.C., Thomas, P.G. and McCullers, J.A. (2009) A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 27, 1192-1200
147Chen, M.W. et al. (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proceedings of the National Academy of Sciences of the United States of America 105, 13538-13543
148Epstein, S.L. et al. (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerging Infectious Diseases 8, 796-801
149Epstein, S.L. et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23, 5404-5410
150Laddy, D.J. et al. (2008) Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3, e2517
151Laddy, D.J. et al. (2009) Electroporation of synthetic DNA antigens offers protection in non-human primates challenged with highly pathogenic avian influenza. Journal of Virology 83, 4624-4630
152Hartikka, J. et al. (2001) Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19, 1911-1923
153Reyes, L. et al. (2001) Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 19, 3778-3786
154Medical News Today (2008) Vical announces breakthrough for pandemic influenza DNA vaccines with preliminary human data.
155Medical News Today (2006) NIAID DNA vaccine for H5N1 avian influenza enters human trial.
156Bangari, D.S. and Mittal, S.K. (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24, 849-862
157Zhu, J., Huang, X. and Yang, Y. (2007) Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. Journal of Virology 81, 3170-3180
158Fooks, A.R. et al. (1995) High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model. Virology 210, 456-465
159Gao, W. et al. (2003) Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362, 1895-1896
160Gomez-Roman, V.R. (2003) HIV/AIDS prevention programs in developing countries are deficient without an appropriate scientific research infrastructure. AIDS 17, 1114-1116
161Lubeck, M.D. et al. (1989) Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proceedings of the National Academy of Sciences of the United States of America 86, 6763-6767
162Sullivan, N.J. et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681-684
163Gao, W. et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. Journal of Virology 80, 1959-1964
164Hoelscher, M.A. et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367, 475-481
165Holman, D.H. et al. (2008) Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 26, 2627-2639
166Hoelscher, M.A. et al. (2007) New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clinical Pharmacology and Therapeutics 82, 665-671
167Hoelscher, M.A. et al. (2008) A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. Journal of Infectious Diseases 197, 1185-1188
168Van Kampen, K.R. et al. (2005) Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23, 1029-1036
169Kostense, S. et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18, 1213-1216
170Catanzaro, A.T. et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. Journal of Infectious Diseases 194, 1638-1649
171Barouch, D.H. et al. (2003) Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. Journal of Virology 77, 8729-8735
172Roy, S. et al. (2007) Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 25, 6845-6851
173Singh, N. et al. (2008) Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Molecular Therapy 16, 965-971
174Yang, Z.Y. et al. (2003) Overcoming immunity to a viral vaccine by DNA priming before vector boosting. Journal of Virology 77, 799-803
175Lundstrom, K. (2003) Alphavirus vectors for vaccine production and gene therapy. Expert Review of Vaccines 2, 447-459
176Pushko, P. et al. (2001) Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. Journal of Virology 75, 11677-11685
177Schultz-Cherry, S. et al. (2000) Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278, 55-59
178Velders, M.P. et al. (2001) Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Research 61, 7861-7867
179Hubby, B. et al. (2007) Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25, 8180-8189
180Aphavax (2007) Alphavax announces results from phase I influenza vaccine clinical trial.
181Ge, J. et al. (2007) Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. Journal of Virology 81, 150-158
182Veits, J. et al. (2006) Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proceedings of the National Academy of Sciences of the United States of America 103, 8197-8202
183Huang, Z. et al. (2003) Recombinant Newcastle disease virus as a vaccine vector. Poultry Science 82, 899-906
184Bukreyev, A. and Collins, P.L. (2008) Newcastle disease virus as a vaccine vector for humans. Current Opinion in Molecular Therapeutics 10, 46-55
185DiNapoli, J.M. et al. (2007) Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. Journal of Virology 81, 11560-11568
186Geisbert, T.W. et al. (2008) Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathogens 4, e1000225
187Geisbert, T.W. et al. (2008) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26, 6894-6900
188Iyer, A.V. et al. (2009) Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01. Vaccine 27, 893-903
189Kapadia, S.U., Simon, I.D. and Rose, J.K. (2008) SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology 376, 165-172
190Roberts, A. et al. (1998) Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. Journal of Virology 72, 4704-4711
191Roediger, E.K. et al. (2008) Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. Molecular Therapy 16, 1161-1169
192Zinkernagel, R.M., Adler, B. and Holland, J.J. (1978) Cell-mediated immunity to vesicular stomatitis virus infections in mice. Experimental Cell Biology 46, 53-70
193Schwartz, J.A. et al. (2007) Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366, 166-173
194Kalhoro, N.H. et al. (2009) A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 27, 1174-1183
195Smith, G.L. and Moss, B. (1983) Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25, 21-28
196Lockey, T.D. et al. (2008) Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. Frontiers in Bioscience 13, 5916-5927
197Altstein, A.D. et al. (2006) Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Archives of Virology 151, 921-931
198Jakeman, K.J., Smith, H. and Sweet, C. (1989) Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins. Journal of General Virology 70, 1523-1531
199Sutter, G. et al. (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032-1040
200Poon, L.L. et al. (2009) Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. Journal of Immunology 182, 3063-3071
201Mayrhofer, J. et al. (2009) Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. Journal of Virology 83, 5192-5203
202Luke, T.C. et al. (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Annals of Internal Medicine 145, 599-609
203Simmons, C.P. et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Medicine 4, e178
204Kashyap, A.K. et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proceedings of the National Academy of Sciences of the United States of America 105, 5986-5991
205Throsby, M. et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942
206Wrammert, J. et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671
207Ekiert, D.C. et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251
208Sui, J. et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature Structural and Molecular Biology 16, 265-273
209Khurana, S. et al. (2009) Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Medicine 6, e1000049
210Khurana, S. et al. (2006) Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. Journal of Virology 80, 2092-2099
Subbarao, K. and Joseph, T. (2007) Scientific barriers to developing vaccines against avian influenza viruses. Nature Reviews Immunology 7, 267-278
Kang, S.M. et al. (2009) Influenza virus-like particles as pandemic vaccines. Current Topics in Microbiology and Immunology 333, 269-289
Kim, J.H. and Jacob, J. (2009) DNA vaccines against influenza viruses. Current Topics in Microbiology and Immunology 333, 197-210
Chen, G.L. and Subbarao, K. (2009) Attacking the flu: neutralizing antibodies may lead to ‘universal’ vaccine. Nature Medicine 15, 1251-1252
Sambhara, S. and Stephenson, I. (2009) Moving influenza vaccines forward. Expert Rev Vaccines 8, 375-377

Related content

Powered by UNSILO

Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target

  • Neetu Singh (a1), Aseem Pandey (a1) and Suresh K. Mittal (a1)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.